Janssen-Cilag International (Janssen) has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Symtuza for the treatment of HIV.

Symtuza (darunavir / cobicistat / emtricitabine / tenofovir alafenamide) is a once-daily, darunavir-based single tablet regimen (STR).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

If approved, Symtuza will be the only darunavir-based STR indicated to treat human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 and older with a body weight of at least 40kg, with genotypic testing guiding use.

The STR combines the efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate).

"Darunavir is one of the most widely used HIV treatments in the European Union due to its ability to control the HIV virus while offering a high barrier to resistance."

Janssen infectious diseases therapeutics global therapeutic area head Lawrence Blatt said: "Darunavir is one of the most widely used HIV treatments in the European Union due to its ability to control the HIV virus while offering a high barrier to resistance.

"We will now be able to combine a complete darunavir-based HIV treatment regimen into a once-daily tablet. We are extremely excited to be one step closer to getting this therapy to people living with HIV and in doing so hope to reduce the treatment burden faced by many living with the virus."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The decision was based on a bioequivalence study, which compared the once-daily STR with the combined administration of the separate agents darunavir at 800mg, cobicistat at 150mg, and a fixed-dose combination of emtricitabine / tenofovir alafenamide at 200mg / 10mg.

The efficacy and safety of the darunavir-based combination is currently being evaluated in a Phase III clinical trial programme.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now